Ralf Pasternack

This inventor holds 10 USPTO granted patents and 5 published patent applications, plus 6 CIPO patents and 12 EPO patents. Top assignees: Zedira Gmbh, Novartis Ag, Dr. Falk Pharma Gmbh. Active years: 2005-2026.

USPTO Granted Patents = 10 (Patent Applications = 5)

% Patents Active = 70.0

CIPO Patents = 6 (Patent Applications = 4)

EPO Patents = 12 (Patent Applications = 12)

Average Co-Inventor Count = 4.2

ph-index = 3

Forward Citations = 12(Granted Patents)

Company Filing History:

Trumpler Gmbh & Co. Chemische Fabrik

patents

where one patent can have more than one assignee

Years Active: 2005-2026

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12661348 - Systemic formulation of a pyridinone derivate for TG2-related diseases (2026-06-23),

2. 11472838 - Inhibitors of blood coagulation factor XIII (2022-10-18),

3. 11072634 - Inhibitors of transglutaminases (2021-07-27),

4. 9434763 - Derivatives of pyridinone as inhibitors for tissue transglutaminase (2016-09-06),

5. 9260680 - Prolamin-reduced beverages and methods for the preparation thereof (2016-02-16),

6. 8808980 - Stabilized open form transglutaminase as a diagnostic indictor for autoimmune diseases (2014-08-19),

7. 8647699 - Method for coating silicone hydrogels (2014-02-11),

8. 8142835 - Method for coating silicone hydrogels (2012-03-27),

9. 7858337 - Process for the manufacture of a composite material (2010-12-28),

10. 6849095 - Agent and method for enzymatically tanning skins (2005-02-01),

Title: Ralf Pasternack: Innovator in Blood Coagulation and Transglutaminase Inhibition

Introduction

Ralf Pasternack is a notable inventor based in Griesheim, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of inhibitors for blood coagulation and transglutaminases. With a total of 10 patents to his name, Pasternack's work has the potential to impact the treatment of various diseases.

Latest Patents

Among his latest patents, Ralf Pasternack has developed inhibitors of blood coagulation factor XIII. This invention relates to a compound of general formula (I) that serves as a novel inhibitor of blood coagulation factor XIII. The methods for synthesizing this compound and its applications for the prophylaxis or treatment of diseases associated with blood coagulation factor XIII are noteworthy advancements in medical science. Additionally, he has created inhibitors of transglutaminases, which also involve a compound of general formula (I). This invention includes methods for producing these compounds, pharmaceutical compositions containing them, and their use in preventing and treating diseases linked to transglutaminases.

Career Highlights

Ralf Pasternack has worked with prominent companies in the pharmaceutical industry, including Zedira GmbH and Novartis AG. His experience in these organizations has allowed him to collaborate with leading experts and contribute to groundbreaking research.

Collaborations

Some of Ralf Pasternack's notable coworkers include Martin Hils and Achim Müller. Their collaboration has likely fostered an environment of innovation and creativity, leading to significant advancements in their respective fields.

Conclusion

Ralf Pasternack's contributions to the field of pharmaceuticals, particularly through his innovative patents, highlight his role as a key inventor in the industry. His work on inhibitors of blood coagulation and transglutaminases showcases the potential for new treatments that can improve patient outcomes.